
Tawanda Gumbo, M.D.
President & CEO, Founder

Tawanda Gumbo, M.D.
President & CEO, Founder
Tawanda Gumbo, MD, is a physician scientist, rising to the rank of Professor of Medicine. Medical School was at the University of Zimbabwe, Residency in Internal Medicine at Case Western Reserve University, and Fellowship in Infectious Diseases at the Cleveland Clinic, in Cleveland, Ohio.
Dr. Gumbo developed several preclinical and clinical laboratory models for fungal, parasitic, bacterial and viral infections, the human immune system, and cancer. He has also developed several mathematical models for translation from the laboratory to patients in the area of therapeutics and quantitative translational pharmacology, and for characterizing disease progression and the immune system in patients based on next generation sequencing and other ‘omics.
He has received research funding for decades from the US NIH, and other private-public funders. Dr. Gumbo is the recipient of numerous awards. His research work has been used to identify optimal doses of the three currently licensed antifungal drugs called echinocandins, anti-TB compounds by the WHO Global TB Program and by national TB programs in numerous countries, the design of new anti-TB drug regimens for children and adults, treatment of non-tuberculous mycobacteria, and together with his team recently identified and characterized safe inhibitors of the fundamental physiologic pathway, sonic hedgehog signaling, and the role of inhibitory immune checkpoints in TB.
He holds several patents for diagnostics, and for monoclonal antibodies that bind to FCER1. Dr. Gumbo is also a published poet and novelist. He also writes the introduction chapter to anti-infective therapy chapter, and the treatment of mycobacterial infections chapter in Goodman & Gilman’s The Pharmacological Basis of Therapeutics, referred to as the “Bible of pharmacology. He has authored about 200 scientific publications on PubMed: VIEW HERE

Johnson Kachidza
CFO

Johnson Kachidza
CFO
Johnson was previously CFO of a data center solutions and IT services provider, which he co-founded and grew internationally to over $200 million in revenues with operations in North America and Brazil and exited. Johnson began his career at blue-chip companies, first as an engineer at General Electric and later as an investment banker at JP Morgan Chase and Merrill Lynch. He began his entrepreneurial career as an independent sponsor where he acquired, invested in, operated, and sold numerous companies in energy services and technology sectors with an aggregate enterprise value of $600 million. Johnson is holder of a US patent for an innovative lighting technology as an engineer at General Electric. VIEW HERE

Moti Chapagain, M.D., PhD.
CSO
MD, PhD; Physician and bench scientist
Extensive training and experience in work with both DNA and RNA viruses and parasites
Has published dozens of seminal papers on epidemiology, molecular pathogenesis, diagnosis and treatment of important human viruses including human polyomavirus JC (JCV), West-Nile virus (WNV) and dengue virus.
Explored role of serotonin receptor blocker risperidone against JCV and roles of minocycline and tumor necrosis factor a receptor 2 in WNV and is expert in virus culture, characterization and quantification
Expert in laboratory hollow fiber models of tuberculosis, Mycobacterium avium-complex, Mycobacterium abscessus, and Mycobacterium kansasii

Wesley Marshall, M.D.
Chief Marketing Officer & Chief Business Development Officer

Wesley Marshall, M.D.
Chief Marketing Officer & Chief Business Development Officer
Wesley, an entrepreneur, and IT enthusiast was previously a financial advisor and before that a medical doctor. He has consulted and financed multiple early stage and growth companies. He is founder of HeliumPro, a company focused on financing, drilling and producing helium on properties throughout the United States, including 14 wells in Arizona and Colorado. Wesley began his career after medicine as Chief Information Officer for a regional brokerage firm maintaining a network of over 200 computers at 6 locations. He progressed to being a licensed financial advisor and money manager, rising through the ranks to become a Vice President and Financial Advisor at Southwest Securities and Ameriprise Financial over two decades. After medical school, he joined the clinical staff at UT Southwestern in the Department of Epidemiology where he led the design, development, and maintenance of a database on war veteran’s Gulf War Syndrome. The data led to over 60 scientific publications, including the Journal of the American Medical Association (JAMA), where Wesley published the first paper based on this data, becoming the youngest physician at the medical school to publish in JAMA. Wesley holds a Doctor of Medicine degree from the University of Texas Southwestern Medical School and a BS in Computer Science from Texas A&M University.

Kevin Smith
Chief Federal Medical Enterprise Business Development Officer & VP for Public-Private Partnership Drug Development

Kevin Smith
Chief Federal Medical Enterprise Business Development Officer & VP for Public-Private Partnership Drug Development